Resources – If you have documents to add please:
Useful Websites – If you have a useful website to add please:
- use the useful website submission pagehttps://www.bopa.org.uk/useful-websites/useful-websites-submissions/
- or email email@example.com
These webinars are aimed at pharmacists who will be drafted into new areas of work during the COVID-19 crisis.
These webinars are FREE and open to all. You can either watch them live and register via the RPS website OR watch the recorded sessions. Recordings can be accessed from the below link on the RPS website or via our BOPA ‘Useful Websites’ link above:
CRUK Your Treatment Diary Video for patients:
to help enable pre-treatment consultations to take place remotely to reduce the need for F2F consultations: https://youtu.be/16ZIZ3Il6UI
Articles from journals:
- COVID-19 in the Cancer Patient, Yeoh, C et al, Anesthesia & Analgesia: April 15, 2020 – Volume Publish Ahead of Print – Issue –
- The Impact of the COVID-19 Pandemic on Cancer Patients, (2020) Al-Quteimat, Osama; Amer, Amer Mustafa, American Journal of Clinical Oncology: April 16, 2020 – Volume Publish Ahead of Print – Issue – doi: 10.1097/COC.0000000000000712
- Caring for our cancer patients in the wake of COVID-19, (2020) Karim Hussien El-Shakankery K et al, British Journal of Cancer https://doi.org/10.1038/s41416-020-0843-5
- Managing COVID-19 in Patients With Cancer: A Double Blow for Oncologists (2020) Sahu et al, JCO Oncology Practice available at https://ascopubs.org/doi/full/10.1200/OP.20.00167
NHSE interim treatment options:
Message from Steve Williamson, NHS England Lead Cancer Pharmacist
29th April 2020 – NHSE Interim treatment options
You may have seen that NICE has published an updated table to the SACT clinical guideline NG161 listing many new Interim treatment options earlier this week. See https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381. There are a couple of points of clarification for providers to note:
- Enzalutamide for prostate cancer states it is subject to confirmation, we can confirm enzalutamide is approved, and there is no need to check for confirmation. A Blueteq form for abiraterone for patients unable to tolerate enzalutamide will be made available in due course.
- Gilteritinib is approved for relapsed /refractory AML and not newly diagnosed AML.
- Nivolumab is approved in MSI-H colorectal cancer, the wording states ‘subject to confirmation’ we can confirm this is approved and there is no need to check for confirmation.
- A blueteq form for polatuzumab will be released in due course as NHSE is currently working with the company to ensure there is stock available for the selected patient group.
We advise all these indications are to be billed through the usual specialised commissioning route, as there is additional COVID19 funding available for them. Any drugs where we have changed the CDF pathway are not funded through CDF as there is separate COVID19 funding for them. We are pleased to note that the manufacturers of many of these drugs have worked with NHS England and offered additional discounts to support the NHS during COVID19.
Password protected resources:
Please visit the forum area for members to see further resources for paid members only (third party resources).
Latest COVID-19 Resources Downloads
Changing Services, Changing Oncology Pharmacy COVID-19 Position StatementDownload
Guidance on testing for asymptomatic healthcare workers and patients in non surgical oncology in UKDownload
Interim treatment change options during the COVID-19 pandemic, endorsed by NHS EnglandDownload
MOGA (the Medical Oncology Group of Australia): Practical considerations for the management of cancer patients during the COVID19 pandemicDownload
Advice for community pharmacists: How can I support cancer patients during the COVID-19 pandemic?Download
NHS: C0119 Advice on maintaining cancer treatment during the COVID-19 responseDownload
Outreach from AstraZeneca UK on COVID-19Download
COVID-19 Strategy for the Interim Management of Testicular Cancer Prepared by the BAUS Section of OncologyDownload
COVID-19 and Palliative, End of LifeDownload
The Medical Journal of Australia: Managing haematology and oncology patients during the COVID-19 pandemic: Interim consensus guidanceDownload
UK Melanoma Focus: COVID-19 Guide C – Managing Melanoma Patients during COVID-19 Pandemic – Surgical Guidance for CliniciansDownload
UK Melanoma Focus: COVID-19 Guide B – Guidelines for Follow-up and SACT for Melanoma during COVID-19 PandemicDownload
UK Melanoma Focus: COVID-19 Guide A – COVID-19 Guidance for People being Treated for MelanomaDownload
UK: COVID-19 and Palliative End of Life and Bereavement Care 22 March 2020Download
Australian: Cancer Council: Cancer and Coronavirus (COVID-19). Patient information.Download
UK NICE: COVID-19 rapid guideline delivery of systemic anticancer treatments 20th March 2020Download
UK NICE: COVID-19 rapid guideline critical care 20th March 2020Download
UK UKCPA: Introduction to Critical Care for pharmacy – Covid – 24th March 2020Download
UK ONE CANCER VOICE: Advice on Coronavirus for people with cancer – PublicationDownload
There are several international pharmacy oncology groups working towards improving patient care and supporting pharmacists within oncology.Explore International Groups
There are several affiliated groups with BOPA. The groups and BOPA work together jointly to promote excellence in the pharmaceutical care of patients with cancer through education, communication, research or innovation.Explore our Affiliated Groups
Subcommittees & working groups information
There are several subcommittees & working groups that report directly to the Executive Committee each month. These subcommittees & working groups support the executive committee and keep the organisation at the forefront of care.Meet our Subcommittees & working groups
The Executive Committee work on behalf of the BOPA members to prioritise and co-ordinate the many activities and workstreams required to achieve our goalsMeet our Executive Committee